Literature DB >> 21104166

Lipid effects of endocrine medications.

Dan V Mihailescu1, Avni Vora, Theodore Mazzone.   

Abstract

Various alterations of lipid homeostasis have a significant role in the pathophysiology of the artherosclerotic process. The effects of usual lipid-lowering agents such as statins, fibrates, or niacin are well known, but other endocrine therapeutic agents could also affect the blood levels of various lipoproteins and, in turn, influence atheroma formation. In this review, we attempt to summarize the effect of several hormonal and non-hormonal endocrine agents on lipid metabolism, including insulin, thyroid hormone, sex hormones, glucocorticoids, growth hormone, and several anti-diabetic agents.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21104166     DOI： 10.1007/s11883-010-0146-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  56 in total

1.  Thiazolidinediones : beyond glycemic control.

Authors:  Kathryn Reynolds; Ronald B Goldberg
Journal:  Treat Endocrinol       Date:  2006

2.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

3.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.

Authors:  P D Thompson; E M Cullinane; S P Sady; C Chenevert; A L Saritelli; M A Sady; P N Herbert
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

4.  Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study.

Authors:  Matteo Pirro; Pascale Mauriège; André Tchernof; Bernard Cantin; Gilles R Dagenais; Jean Pierre Després; Benoît Lamarche
Journal:  Atherosclerosis       Date:  2002-02       Impact factor: 5.162

5.  Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients.

Authors:  Mitsuru Ito; Takeshi Arishima; Takumi Kudo; Eijun Nishihara; Hidemi Ohye; Sumihisa Kubota; Shuji Fukata; Nobuyuki Amino; Kanji Kuma; Ichiro Sasaki; Tetsuya Hiraiwa; Toshiaki Hanafusa; Junta Takamatsu; Akira Miyauchi
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

6.  Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia.

Authors:  José Augusto Soares Barreto-Filho; Marta Regina S Alcântara; Roberto Salvatori; Martha Azevedo Barreto; Antônio Carlos Sobral Sousa; Valquíria Bastos; Anita Hermínia Souza; Rossana Maria C Pereira; Peter E Clayton; Matthew S Gill; Manuel Hermínio Aguiar-Oliveira
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

7.  Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Authors:  M B Toft-Nielsen; S Madsbad; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

8.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

9.  Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans.

Authors:  R V Farese; T J Yost; R H Eckel
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

10.  Relationship of sex hormones to lipids and lipoproteins in nondiabetic men.

Authors:  S M Haffner; L Mykkänen; R A Valdez; M S Katz
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958
View more
  1 in total

Review 1.  Diabetes Dyslipidemia.

Authors:  Jonathan D Schofield; Yifen Liu; Prasanna Rao-Balakrishna; Rayaz A Malik; Handrean Soran
Journal:  Diabetes Ther       Date:  2016-04-07       Impact factor: 2.945
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.